Acelarin gets FDA Fast Track designation for treatment of biliary tract cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a phase III study, NuTide:121, for the first-line treatment of patients with advanced biliary tract cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login